NCT01431053Unknown2 期
Phase 2 Study of Aspirin Plus Exemestane Comparing With Exemestane Alone in the Adjuvant Treatment of Postmenopausal Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 160
- 试验地点
- 1
- 主要终点
- Quality of Life
研究概览
简要总结
This is a phase II study to assess efficacy/safety of Exemestane with or without Aspirin as the adjuvant treatment in postmenopausal breast cancer patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 80 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Breast cancer after surgery postmenopausal
排除标准
- •contraindication of aspirin
研究组 & 干预措施
Exemestane + Aspirin
Experimental
干预措施: aspirin (Drug)
Exemestane + Aspirin
Experimental
干预措施: Exemestane (Drug)
Exemestane
Active Comparator
干预措施: Exemestane (Drug)
结局指标
主要结局
Quality of Life
时间窗: 4 years
次要结局
未报告次要终点
研究者
Peng Yuan
Associate Chief Physician
Chinese Academy of Medical Sciences
研究点 (1)
Loading locations...
相似试验
终止
1 期
Exemestane With Sunitinib (SUTENT®) in Metastatic Breast CancerMetastatic Breast CancerNCT00905021Baylor Breast Care Center4
Unknown
2 期
Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast CancerHormone Receptor Positive Malignant Neoplasm of BreastNCT02025712Organisation for Oncology and Translational Research35
终止
2 期
Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal WomenBreast NeoplasmsNCT00040014Pfizer100
撤回
2 期
Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast CancerHormone-receptor Positive Breast CancerNCT00615524GlaxoSmithKline
已完成
2 期
Exemestane in Post-Menopausal Women With NSCLCNon-Small Cell Lung CancerNCT02666105Masonic Cancer Center, University of Minnesota6